Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients
Open Access
- 16 May 2019
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 53 (6) , 1801824
Abstract
There remains an unmet need for effective, well-tolerated therapeutic options in paediatric patients with not fully controlled asthma, for whom safety is of paramount importance.Data were pooled from five randomised, double-blind, placebo-controlled studies evaluating tiotropium 5 or 2.5 µgversusplacebo add-on therapy in patients with symptomatic asthma aged 1–17 years. Analysis included adverse events (AEs) and serious AEs (SAEs) reported throughout and for 30 days following treatment.Of 1691 patients treated, 1119 received tiotropium. Reporting of AEs was low and comparable across all groups: tiotropium 5 µg (51%), tiotropium 2.5 µg (51%) and placebo (54%). Reporting of drug-related AEs, those leading to discontinuation and SAEs was also low and balanced between treatment groups, irrespective of age, disease severity or sex. The number of AEs related to asthma symptoms and exacerbations was lower with tiotropium (5 µg) than with placebo, particularly during the seasonal peaks of these AEs.This comprehensive analysis of a large safety database allowed subgroup analyses that are often impractical with individual trials and provides further support for the safety of once-daily tiotropium Respimat add-on therapy in paediatric patients with symptomatic asthma.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 31 references indexed in Scilit:
- β2-Agonist Therapy in Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Tiotropium in Asthma Poorly Controlled with Standard Combination TherapyNew England Journal of Medicine, 2012
- Effect of Inhaled Glucocorticoids in Childhood on Adult HeightNew England Journal of Medicine, 2012
- Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trialJournal of Allergy and Clinical Immunology, 2011
- Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City ChildrenNew England Journal of Medicine, 2011
- Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fallJournal of Allergy and Clinical Immunology, 2009
- Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary DiseaseJAMA, 2008
- Individual case safety reports in children in commonly used drug groups – signal detectionBMC Clinical Pharmacology, 2008
- The impact of inadequately controlled asthma in urban children on quality of life and productivityAnnals of Allergy, Asthma & Immunology, 2007
- The global burden of asthma: executive summary of the GINA Dissemination Committee ReportAllergy, 2004